NCT03398967 and NCT03166878 (both at phase 1/2), designed to target CD19, CD20, and CD22 on B cells, are associated with B cell leukemia and B cell lymphoma immunotherapy [402]. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.